Drugmaker to settle nearly 80,000 Zantac lawsuits for up to $2.2 billion
UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level Zantac cases. The lawsuits claimed that the now-discontinued version of the heartburn drug caused cancer,
GSK says $2.2bn settlement resolves most Zantac litigation
GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the settlements, which will be funded through "existing resources," and said there will be "no changes to GSK's growth agenda or investment plans for R&D as a result."
Zantac’s Developer Settles Lawsuits Claiming Cancer Link
GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.
GSK settles vast majority of Zantac claims for $2.2 billion
The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn remedy causes cancer
Zantac maker GSK agrees to pay $2.3 bn in US settlements
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer.
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
UK firm GSK to pay $2.2bn over Zantac cancer claims
UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.
GSK Settles Zantac Lawsuits: A New Chapter for the Controversial Drug
The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that certain versions might contain impurities linked to cancer,
GSK settles 4 Zantac lawsuits claiming heartburn drug caused cancer
GSK announced Wednesday that it has settled four cases in California that were linked to its now-discontinued heartburn drug Zantac. The company didn't disclose a settlement figure.
GSK Shares Climb on $2.2 Billion Zantac Lawsuit Settlement
GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac caused cancer.
GSK surges 6.5% after $2.2 billion Zantac lawsuits settlement
Shares of GSK rose as much as 6.5% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits in the United States that claimed its discontinued heartburn drug Zantac caused cancer.
FiercePharma3d
GSK will pony up $2.2B to resolve 80K Zantac cases
The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.
devdiscourse3d
Breaking Health News: Investment Moves, Drug Updates and Disease Outbreaks
This summary covers recent health events including investment in German firm Gerresheimer, updates on the U.S. Medicare drug ...
Medpage Today on MSN5d
Acne Treatments Taken Right Off the Shelf Had High Levels of Benzene
Dozens of over-the-counter acne products had very high levels of the known carcinogen benzene, even when they were taken ...
FiercePharma1d
Sanofi enters talks with private equity firm to sell controlling stake in consumer health unit Opella
With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a ...